Surgery for Patients With cT3/4N2M0, Stage IIIB NSCLC. Is It Time to Redefine Resectability?

Surgery for Patients With cT3/4N2M0, Stage IIIB NSCLC. Is It Time to Redefine Resectability?

Introduction: Chemoradiation followed by durvalumab is considered a standard approach for patients with locally advanced NSCLC. With improvements in perioperative and neoadjuvant approaches, there is renewed interest in offering surgery to carefully selected patients with cT3/4N2 stage IIIB cancer....

Full description

Saved in:
Bibliographic Details
Main Authors: J. Humberto Rodriguez-Quintero, MD, MPH, Rajika Jindani, MD, MPH, MS, Roger Zhu, MD, Isaac Loh, Mohamed K. Kamel, MD, Anne Montal, MD, Marc Vimolratana, MD, MS, Neel P. Chudgar, MD, Nitin Ohri, MD, MS, Balazs Halmos, MD, MS, Brendon M. Stiles, MD
Format: Article
Language:English
Published: Elsevier 2025-01-01
Series:JTO Clinical and Research Reports
Subjects:
Unresectable
Definitive chemoradiation
Stage IIIB NSCLC
Neoadjuvant therapy
Perioperative approaches
Online Access:http://www.sciencedirect.com/science/article/pii/S266636432400136X
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S266636432400136X

Similar Items